Global Information
회사소개 | 문의 | 비교리스트

반코마이신 내성 황색포도상구균(VRSA) 감염증 : 파이프라인 리뷰

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 12월 상품코드 303576
페이지 정보 영문 62 Pages 배송안내
가격
US $ 2,000 ₩ 2,548,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 5,096,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,645,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


반코마이신 내성 황색포도상구균(VRSA) 감염증 : 파이프라인 리뷰 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 12월 페이지 정보 : 영문 62 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

반코마이신 내성 황색포도상구균(VRSA) 감염증은 황색포도상구균(Staphylococcus Aureus)이라는 세균이 항생물질 반코마이신에 대한 약제 내성을 가지게되면서 발병하는 질환입니다. 주요 위험인자로는 강력한 항생물질을 부적절한 방법으로 섭취하는 것(에 의해 세균이 항생물질에 대한 내성을 강화시키는 것), 면역계 약화, 장기간 입원 생활 등이 포함됩니다. 주요 증상으로 고열, 오한, 기침, 흉통, 호흡 곤란, 빈맥 등을 들 수 있습니다.

세계 각국에서의 반코마이신 내성 황색포도상구균(VSRA : Vancomycin-Resistant Staphylococcus Aureus) 감염증 치료용 파이프라인 제품 개발 상황에 대해 분석했으며, 제품 개발·출시의 최신 동향, 임상시험 각 단계에 있는 제품, 주요 기업 개요, 주요 약제 개요, 최신 업계 동향 등의 정보를 전해드립니다.

서론

  • 조사 범위

반코마이신 내성 황색포도상구균(VRSA) 감염증 개요

치료제 개발

  • 개요
  • 파이프라인 제품 비교 분석

반코마이신 내성 황색포도상구균(VRSA) 감염증 : 기업에서 개발중인 치료제

반코마이신 내성 황색포도상구균(VRSA) 감염증 : 대학/기관에서 연구중인 치료제

반코마이신 내성 황색포도상구균(VRSA) 감염증 : 파이프라인 제품 개요

  • 임상 단계 제품
  • 초기 단계 제품

반코마이신 내성 황색포도상구균(VRSA) 감염증 : 기업에서 개발중인 제품

반코마이신 내성 황색포도상구균(VRSA) 감염증 : 대학/기관에서 연구중인 제품

반코마이신 내성 황색포도상구균(VRSA) 감염증 치료제 개발에 참여하고 있는 기업

  • CrystalGenomics, Inc.
  • Debiopharm International SA
  • iNtRON Biotechnology Inc.
  • Wockhardt Limited

반코마이신 내성 황색포도상구균(VRSA) 감염증 : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

약제 개요

반코마이신 내성 황색포도상구균(VRSA) 감염증 : 최근의 파이프라인 동향

반코마이신 내성 황색포도상구균(VRSA) 감염증 : 휴지중인 프로젝트

반코마이신 내성 황색포도상구균(VRSA) 감염증 : 개발이 중지된 제품

부록

KSM 16.07.14

List of Tables

List of Tables

  • Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Amprologix Ltd, 2021
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by CrystalGenomics Inc, 2021
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Destiny Pharma Plc, 2021
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Lysimmune BioScience, 2021
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Roivant Sciences Ltd, 2021
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Sano Chemicals Inc, 2021
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by TAXIS Pharmaceuticals Inc, 2021
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by TGV-Inhalonix Inc, 2021
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Therapeutic Systems Research Laboratories Inc, 2021
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Wockhardt Ltd, 2021
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects, 2021
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drugs In Development, 2021, provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline landscape.

Vancomycin resistant staphylococcus infection is a condition caused by bacteria (germs). This infection occurs when bacteria, called Staphylococcus aureus or Staph, becomes resistant (not killed) to the antibiotic medicine vancomycin. Risk factors include taking strong antibiotics the wrong way may cause the bacteria to develop resistance to the antibiotics, weak immune system and staying in the hospital too long. Symptoms include fever, chills, cough, chest pain, trouble breathing, and a fast heartbeat.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 2, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 5 and 2 molecules, respectively.

Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Overview
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Companies Involved in Therapeutics Development
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Drug Profiles
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects
  • Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q